{"schema_version":"secwatch.filing_event.v1","accession":"0001933414-25-000057","form_type":"8-K","ticker":"MLYS","cik":"0001933414","company_name":"Mineralys Therapeutics, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.498967+00:00","generated_at":"2026-05-22T00:39:51.675730+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.88,"calibrated_materiality_score":0.88,"confidence":"high","headline":"Mineralys reports positive pivotal trial results; Q1 net loss $42.2M; cash $343M","bullets":["Launch-HTN: 50 mg lorundrostat achieved 9.1 mmHg placebo-adjusted SBP reduction at week 6 (p<0.0001).","Advance-HTN: 50 mg cohort met primary endpoint; 7.9 mmHg placebo-adjusted SBP reduction (p=0.001).","Cash, equivalents and investments $343.0M as of March 31, 2025, vs $198.2M at Dec 31, 2024.","Net loss for Q1 2025 was $42.2M, up from $31.5M in Q1 2024; R&D expenses rose to $37.9M.","Appointed Eric Warren as Chief Commercial Officer; pre-NDA meeting with FDA expected Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001933414-25-000057","json":"https://secwatch.observer/filing/0001933414-25-000057.json","markdown":"https://secwatch.observer/filing/0001933414-25-000057.md","text":"https://secwatch.observer/filing/0001933414-25-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933414/000193341425000057/0001933414-25-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933414/000193341425000057/mlys-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T00:39:51.675730+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}